Not a member? To register
Evonik Industries AG (Essen, Germany) has officially begun the structure of its $220 million global production facility for specialty pharmaceutical lipids in Lafayette, Indiana, USA. other nucleic acid therapies. The plant is expected to become operational in 2025.
“Our new Lipid Innovation Center will secure tomorrow’s healthcare inventions. With this investment, we are strengthening our leadership position in the pharmaceutical industry. We are privileged to assist the United States in its pandemic preparedness and enable the advancement of cutting-edge technology. medicines,” said Christian Kullmann, CEO of Evonik.
During the COVID-19 pandemic, Evonik plays a key role in ensuring the availability of functional excipients for primary vaccine producers. Evonik’s Healthcare business is a component of the Life Sciences Division, Nutrition
“This new global facility will strengthen Evonik’s unique position as CDMO in the pharmaceutical industry. Whether it’s progressive or large-scale quantities, formulas, or filling and finishing, our RNA-based drug partners can count on us for the process. ” said Johann-Caspar Gammelin, president of the Division of Nutrition.
The total investment in the utility-scale lipid facility is $220 million. The U. S. government The U. S. Department of Agriculture has signed a cooperation agreement with Evonik to share costs of up to $150 million with its Biomedical Advanced Research and Development Authority (BARDA), a component of the U. S. U. S. Strategic Preparedness and Response Administration (ASPR) and Social Services (HHS) of the Department of Health. BARDA coordinated procurement assistance with the Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND).
The Evonik Lipid Innovation Center will be built on the grounds of Evonik Tippecanoe Laboratories, which is one of the world’s largest contract production services for active pharmaceutical ingredients (APIs) and the largest Evonik of the moment in the United States. enable the immediate scaling and production of a variety of specialty lipids with high-quality criteria to serve long-term RNA generation programs in infectious disease control, cancer immunotherapy, protein replacement, and gene therapy.
In early March 2023, Evonik opened a new cGMP facility in Hanau, Germany, to expand and manufacture smaller batches of lipids. This lipid release facility will supply consumers with lipid quantities for small-scale clinical and advertising production. This facility complements Evonik’s existing advertising production network and laboratory, which includes formula functions in Vancouver, Canada, and production and filling and finishing functions in Birmingham, Alabama, USA. U. S.
The inaugural rite of the Indiana-based Lipid Innovation Center on March 29, 2023 brought together federal government officials, Indiana Governor Eric Holcomb and local officials from the greater Lafayette area, who were joined by Evonik CEO Christian Kullmann and members of the company’s executive. Board of Directors and Supervisory Board.
Chemical engineering and content delivered weekly